This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Key Highlights


Compared with standard chemotherapy, BESPONSA offers in R/R ALL:

Title

With BESPONSA, bridge more of your R/R ALL patients to curative therapy than with standard chemotherapy1

​​​​​​​*Data for CR/CRi from the prespecified primary analysis of n = 109 in either arm. Between-group differences were 51.4% (97.5% CI, 38.4–64.3) for CR/CRi and 50.3% (97.5% CI, 29.9–70.6) for CR/CRi (MRD negative); p < 0.001.
​​​​​​​The two-sided p values for between-group differences were determined by means of the chi-square test or Fisher’s exact test (if any cell count was < 5).
†Data for transplant and OS analysis from the ITT population: 2-year OS 22.8% vs 10.0% with standard chemotherapy.2 ‡HR,
 0.751 (97.5% CI, 0.588–0.959; 2-sided p-value = 0.0210).
Additional OS data are available in the current BESPONSA SmPC.2 A modified analysis of median OS data, carried out by the European Medicines Agency, demonstrated a significantly longer median OS with BESPONSA compared with standard chemotherapy.5

CI, confidence interval; CR, complete remission; CRi, complete remission with incomplete haematological recovery of peripheral blood counts; HR, hazard ratio; HSCT, haematopoietic stem cell transplantation; ITT, intention-to-treat; MRD, minimal residual disease; OS, overall survival; QoL, quality of life; R/R ALL, relapsed/refractory acute lymphoblastic leukaemia; SC, standard chemotherapy; SmPC, Summary of Product Characteristics.

Explore more

Developments in Leukaemia Care

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn More

Key data from the INO-VATE study 

Here Dr. Anna Castleton discuss the key data for BESPONSA vs standard care from the INO-VATE study

Learn More

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References
  1. Kantarjian HM, et al. N Engl J Med 2016;375:740–753
  2. BESPONSA Summary of Product Characteristics for Great Britain click here. BESPONSA Summary of Product Characteristics for Northern Ireland click here.
  3. Marks DI, et al. Cancer Med 2019; 5959-5968
  4. Kantarjian HM, et al. Cancer 2018; 124; 2151-2160
  5. European Medicines Agency. EPAR, inotuzumab (EMA/289046/2017). Available at: https://www.ema.europa.eu/en/documents/assessment-report/besponsa-epar-public-assessment-report_en.pdf [accessed August 2021]
PP-INO-GBR-0496. August 2021

Access Support and Resources to read the guidelines, watch videos with leading specialists. 

Access here

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No